OncoSec Medical Inc (ONCSQ) Financiero

OncoSec Medical, Inc. is a biotechnology company focused on designing, developing and commercializing therapies and proprietary medical approaches to stimulate and to guide an anti-tumor immune response for the treatment of cancer. The company is headquartered in Ewing, New Jersey and currently employs 40 full-time employees. The company went IPO on 2015-05-29. The firm is focused on developing intratumoral immunotherapies to stimulate the patient’s immune system to target cancer cells and eradicate disease. Its lead immunotherapy investigational product candidate-TAVO (tavokinogene telseplasmid)-enables the intratumoral delivery of DNA-based interleukin 12 (IL-12), a naturally occurring protein with immune-stimulating functions. The therapeutic approach TAVO-EP, which employs electroporation, is designed to produce a localized expression of IL-12 in the tumor microenvironment and, thereby, stimulate the immune system to target and attack tumors.